A phase I, single-centre, non-randomised, open-label, pharmacokinetic and mass balance study of orally administered [14C]-AZD9291 in healthy male volunteers

Trial Profile

A phase I, single-centre, non-randomised, open-label, pharmacokinetic and mass balance study of orally administered [14C]-AZD9291 in healthy male volunteers

Completed
Phase of Trial: Phase I

Latest Information Update: 23 Oct 2015

At a glance

  • Drugs Osimertinib (Primary)
  • Indications Non-small cell lung cancer
  • Focus Pharmacokinetics
  • Sponsors AstraZeneca
  • Most Recent Events

    • 15 Sep 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov .
    • 25 Jun 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
    • 30 May 2014 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top